Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00217464 · ClinicalTrials.gov registry record · Phase 2
Fulvestrant in Treating Patients With Recurrent Prostate Cancer
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00217464 is a Phase 2 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 17 participants.
The verdict
NCT00217464, a Phase 2 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells. PURPOSE: This phase II trial is studying how well fulvestrant works in treating patients with recurrent prostate cancer.
Interventions
- DRUG fulvestrant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2004-06 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00217464
The ClinicalTrials.gov registry entry for NCT00217464 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fulvestrant is the first listed.
NCT00217464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00217464 about?
NCT00217464 is a clinical study titled "Fulvestrant in Treating Patients With Recurrent Prostate Cancer". RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells. PURPOSE: This phase II trial is studying how well fulvestrant works in treating patients with recurrent prostate cancer.
What is the current status of trial NCT00217464?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2004-06. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00217464?
The interventions under investigation include: fulvestrant (DRUG).
Who is sponsoring clinical trial NCT00217464?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.